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Abstract
The surgical specimens from 51 men submitted to radical prostatec-
tomy for localized prostate cancer were examined by immunohis-
tochemistry using proliferation cell nuclear antigen (PCNA) mono-
clonal antibody to evaluate the proliferative index (PI). The relation-
ship between PI, biological variables and p53 protein expression was
evaluated by immunohistochemistry. PI was low in invasive localized
prostate carcinoma (mean, 12.4%) and the incidence of PCNA-posi-
tive cells was significantly higher in tumors with p53 expression (P =
0.0226). There was no statistical difference in PCNA values when
biological parameters such as Gleason score, tumor volume, extrapro-
static involvement, seminal vesicle infiltration or lymph node metas-
tasis were considered. We conclude that proliferative activity is usu-
ally low in prostate carcinoma but is correlated with p53 immune
staining, indicating that p53 is important in cell cycle control in this
neoplasm.
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Introduction
The assessment of proliferation is impor-
tant to characterize the malignant phenotype
and biological behavior of neoplasms. Sev-
eral techniques such as tritium [3H]-thymi-
dine radioautography, 5-bromo- and 5-iodo-
deoxyuridine (Brdu) immunohistochemistry,
mitotic figure counts, S-phase evaluation by
flow cytometry or the observation of living
cells in tissue culture by phase contrast mi-
croscopy are some of the tools to determine
the proliferative activity. Proliferation cell
nuclear antigen (PCNA) is an auxiliary en-
zyme protein for DNA polymerase-delta in-
volved in DNA synthesis during the S-phase
of the cell cycle (1,2). The PCNA antibody
can be used in formalin-fixed, paraffin-em-
bedded tissue to evaluate cell proliferation.
Cells in the late G1 and S phase show strong
nuclear staining, which is not detected in
mitotic or arrested cells. In prostate carcino-
ma the proliferative activity has been related
to disease progression (3) and risk of death
(4) and has been used to demonstrate high-
grade prostatic intraepithelial neoplasia (HG-
PIN) as a precursor of the invasive carcinoma
(5). p53 is a tumor suppressor gene important
in cell cycle control, DNA repair and apopto-
sis (6). Its role in prostate cancer has been
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evaluated by many investigators since Isaacs
(7) described a suppression of tumorigenesis
in prostate cancer cell lines by transfecting
wild type p53. The most common alteration
in the p53 gene, located in the 17p13.1 chro-
mosome, is the missense mutation, that pro-
duces a protein with extended half-life that
can be detected by immunohistochemistry
using monoclonal antibodies (8). p53 immu-
nostaining has been related to high histologi-
cal grade, DNA aneuploidy and proliferation
(9). Others consider the p53 mutation to be a
late event related to androgen-independent
growth (10). The aim of the present study
was to evaluate proliferation, its relation to
p53 expression and other biological vari-
ables. A retrospective study using paraffin-
embedded tissue from 51 men submitted to
radical prostatectomy for localized prostate
cancer was performed using anti-PCNA anti-
body (PC10) for the evaluation of prolifera-
tive activity. The PI, expressed as percent of
positive cells in 500 cells sampled, was com-
pared with p53 protein expression, Gleason
score, tumor volume, extraprostatic involve-
ment, seminal vesicle infiltration and lymph
node metastasis.
Material and Methods
Fifty-one patients with prostate cancer
clinically staged as T1 and T2N0M0 (11)
were submitted to radical prostatectomy be-
tween March and June 1997 at the Sírio
LibanŒs Hospital. The specimens were fixed
in buffered formalin for 4 to 16 h. The entire
surgical margin was stained with India ink.
The left and right lobes were separated, 3-
mm transversal serial sections were obtained
from each lobe and the whole tissue was
submitted to histological examination. Sec-
tions of bladder neck, prostate apex, seminal
vesicles and pelvic lymph nodes were also
examined. An average of 10 to 16 slides
from each gland were examined. The Gleason
score was used for grading. Tumor volume
was evaluated using a grid below the slides
on which the tumor areas were previously
sketched out. Tumor percentage was calcu-
lated by counting the number of squares on
the grid involved by tumor and its relation to
the number of squares of the entire area of
the whole section on each slide. The mean
percentage of tumor affecting the gland was
considered and will be referred to as tumor
volume in the text. The extraprostatic in-
volvement was defined as tumor infiltrating
the adipose tissue or neurovascular plexus.
Only the parenchymatous infiltration of the
seminal vesicle was considered positive. The
tumors were divided into two groups for
statistical comparison: favorable group which
included tumors without extraprostatic in-
volvement, seminal vesicle infiltration or
lymph node metastasis, and the unfavorable
group which included tumors with extrapro-
static tissue involvement with seminal vesicle
infiltration and/or lymph node metastasis.
Immunohistochemistry
Three-micrometer sections from paraf-
fin-embedded specimens on adhesive-coated
slides were submitted to heat antigen re-
trieval using a domestic microwave oven
(high power) and citrate buffer, pH 6.0, 3
times, for 8 min (12). The endogenous per-
oxidase activity was quenched by exposing
the sections to a solution of H2O2 for 5 min.
The sections were incubated overnight with
anti-PCNA (PC10) and anti-p53 (DO-7)
monoclonal antibodies (Dako, Carpinteria,
CA) at 1:100 dilution in PBS at 4oC. Biotin-
ylated antimouse immunoglobulin G was
applied at 1: 400 dilution for 60 min at room
temperature (RT). After rinsing with PBS
for 30 min, slides were incubated with per-
oxidase-conjugated streptavidin at 1:400 di-
lution for 45 min at RT and then rinsed with
PBS for 30 min. Color was developed by
incubating the slides with 0.06% diamino-
benzidine in PBS for 15 min; slides were
then rinsed in tap water, counterstained with
Harris hematoxylin, dehydrated and cover-
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slipped (13). One slide that best represented
the tumor was selected and at least 500 cells
in a hot spot area were counted with a
high-power field light microscope. Only the
dark nuclear staining was considered posi-
tive for PCNA and p53. The percentage of
anti-PCNA-stained cells and 3 groups of p53
expression were used for statistical analysis.
p53 expression was considered negative when
less than 20% of cells were stained, low
when p53 was between 20 to 50% and high
when the percentage was higher than 50%.
Statistics
The patients were divided into favorable
and unfavorable groups considering inva-
sion of periprostatic tissue, seminal vesicle
infiltration and lymph node metastasis. Mean
PCNA values were compared between these
groups by the chi-square test. Differences
among the three groups in p53 immune ex-
pression in relation to PCNA were evaluated
by analysis of variance.
Results
Patient age ranged from 50 to 74 years
(mean, 65 years; median, 67 years). The
Gleason score was 3-6 in 32 patients
(62.7%) and 7-10 in 19 (37.3%). The mean
tumor volume was 23.8% (median, 20%)
ranging from 0.6 to 79%. Twenty-six (51%)
patients had less than a 20% tumor volume
and 25 (49%) more than a 20% tumor vol-
ume. Thirty-three (64.7%) patients were
staged as T1-T2N0M0, 17 (33.3%) as
T3N0M0 and 1 (2%) as T3N1M0. Extra-
prostatic tissue extension was observed in
13 patients (25.5%), seminal vesicle in-
volvement in 11 (21.6%) and lymph node
metastasis in only 1 case (2%). The percent
of anti-PCNA-stained cells ranged from
0.5 to 46% (mean, 12.4%; median, 10%)
(Figure 1). Eleven patients (21.6%) were in
the unfavorable group and the PCNA value
ranged from 3 to 29% (mean, 12.85%; me-
Figure 1 - Immunohistochemistry of a prostate adenocarcinoma using anti-PCNA (PC10)
antibody. The dark nuclei are positive.
Table 1 - Proliferative cell nuclear antigen (PCNA)
values of favorable and unfavorable groups con-
sidering extraprostatic involvement, seminal
vesicle infiltration and lymph node metastasis.
*P = 0.8460. PCNA data are reported as percent
of PCNA-stained cells.
Group PCNA (%)
N Mean Median Range
(± SD)
Favorable 40 12.28 ± 8.89* 10 0.5-46
Unfavorable 11 12.85 ± 7.08* 12 3.0-29
dian, 12%). The remaining cases (78.4%)
were in the favorable group, with PCNA
ranging from 0.5 to 46% (mean, 12.28%;
median, 10%). There was no significant
difference between groups (P = 0.8460)
(Table 1). In 8 tumors p53 was considered
negative, in 21 there was low immune reac-
tivity and in 22 high immune reactivity
(Figure 2). Mean p53 levels were 45.9%,
ranging from 0 to 99% of positive cells.
There was a statistically significant differ-
ence among the mean PCNA values of the
three groups of p53 immune expression.
Mean PCNA was 8.3% in the p53-negative
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group, 10.2% in the low expression group
and 16% in the high expression group (P =
0.0226) (Table 2). No significant correla-
tion was detectable between PCNA and
any of the biological variables considered
separately.
Discussion
The index of tumor cell proliferation
can be used to define the behavior and
prognosis in a series of human tumors, in-
cluding breast cancer (14) and sarcomas
(15). Proliferation activity in prostate can-
cer has been assessed by immunohistochem-
istry using Ki-67 monoclonal antibody
(16,17), PCNA (18) and tritium[3H]-thymi-
dine or bromodeoxyuridine labeling (19,20).
Some studies demonstrated progressively
rising levels of proliferative index (PI) val-
ues from PIN to invasive and metastatic
carcinoma, illustrating the cancer progres-
sion (19,20). The mean PI values have been
shown to range from 1.7 to 17.6% indicat-
ing low cell turnover consistent with a natu-
ral slow disease progression. Visakorpi et
al. (9), studying a heterogeneous group of
patients including advanced metastatic dis-
ease using the same antibody (PCNA-PC10),
found mean PI values ranging from 0.3 to
29.1% and established a strong association
between proliferation and p53 immunore-
activity. We could also demonstrate a strong
association between PI value and p53 ex-
pression in our cases and since only local-
ized prostate cancers were selected a lower
PI value was determined, with a mean PCNA
value of 12.4% and a median of 10%.
Montironi et al. (18), also using PCNA
antibody, found the same mean PI value in
their cases and were able to correlate PI to
histological grading. In our study we were
unable to show a relationship between PI
and Gleason grade, tumor volume or stage.
Bubendorf et al. (21) obtained the same
results using the MIB-1 antibody directed
at recombinant parts of Ki-67 to evaluate
proliferation only in localized prostate ad-
enocarcinoma. They found a mean PI value
of 7.7% and were also unable to correlate
proliferation with tumor stage or histologi-
cal grade. The tumor growth results from
high cellular proliferation and a low rate of
cell death by apoptosis. The p53 protein
coded by the p53 gene, localized on the
short arm of chromosome 17, is important
for the cell-cycle control. This protein acts
as a DNA guardian allowing expression of
DNA repair genes as well as promoting
apoptosis (6). In more than 50% of human
tumors the p53 protein is inactivated. The
Figure 2 - Immunohistochemistry of a prostate adenocarcinoma using anti-p53 (DO7)
antibody. Only the dark nuclei are considered to be positive.
Table 2 - Proliferative cell nuclear antigen (PCNA)
values and p53 immune expression.
PCNA data are reported as percent of PCNA-
stained cells. *P = 0.0226.
p53 PCNA (%)
expression
N Mean Median Range
(± SD)
Negative 8 8.31 ± 4.89* 10.5 0.5-13
Low 21 10.19 ± 6.20* 9.0 1.0-29
High 22 16.02 ± 10.06* 15.5 4.0-46
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most common cause of p53 inactivation is
missense mutation that promotes protein
stabilization, allowing detection by immu-
nohistochemistry (8). There are also alter-
native ways for inactivation: a) associa-
tions of p53 protein with other tumor sup-
pressor genes such as WT1 and IRF1; b)
inactivation by binding with oncoprotein-
like adenovirus E1B and Mdm2 (murine
double minute 2) protein (22), and c) de-
struction via a ubiquitin-dependent pro-
teolytic pathway after binding to E6 pro-
tein, the product of human papillomavirus
(HPV) 16 and 18 (23). We found p53 ex-
pression in 84% of our patients, with a
mean value of 45.9%. Bauer et al. (24)
found almost the same proportion of p53
expression (70.5%) using the same meth-
odology, and the low or high expression
was considered important to predict the
relative risk of recurrence. The high level of
nuclear p53 protein accumulation detected
in our cases may be related to methodology
since we used heat antigen retrieval with a
microwave oven and citrate buffer, which
considerably enhances antigen detection,
unmasking antigenic epitopes (25,26). This
method was not mentioned in other studies
(9,10). We could not demonstrate a correla-
tion between proliferation and biological
parameters in localized prostate carcinoma,
but we were able to find a strong relation-
ship between PI and p53 protein expression
(P = 0.0226), suggesting that P53 mutation
gives a proliferative advantage to a sub-
group of these neoplasms.
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